Tasimelteon
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
609799-22-6- Standard-SMILES
CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2- InChIKey
PTOIAAWZLUQTIO-GXFFZTMASA-N- Summenformel
- C15H19NO2
- Durchschnittliche Molmasse
- 245,322 g/mol
- Monoisotopische Masse
- 245,14157885
Namen und Bezeichner
- Bevorzugter Name
- Tasimelteon
- IUPAC
- N-{[(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
- Englischer Name
- Tasimelteon
- Summenformel
- C15H19NO2
- Molmasse
- 245.32
Namen und Synonyme
BMS 214778Tasimalteon(1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamideTasimelteon (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamideMA 1VEC 162asimelteontasimelteonHesimiqiongTasimelteon-d5
Datenbank-Bezeichner
- CAS
609799-22-6- PubChem CID
- 10220503
- DTXSID
DTXSID70209826- ChEMBL
CHEMBL2103822- ChEBI
CHEBI:79042- UNII
- SHS4PU80D9
- EC Number
- 612-059-5
- Nikkaji
- J3.640.465E
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 78 °C · 78 °C
- Siedepunkt
- 442.6 · 442.6±24.0 °C(Predicted)
- Dichte
- 1.145 · 1.145
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 16.43 · 16.43±0.46(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- InChI
- InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
- InChIKey
- PTOIAAWZLUQTIO-GXFFZTMASA-N
- SMILES
- C(NC[C@@H]1C[C@H]1C1=C2C(=CC=C1)OCC2)(=O)CC
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- WGK 3
- hs_code
- 2937.90.9000
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Repr. 2STOT SE 3
Chemie und Industrie
Anwendungen
BeschreibungTasimelteon, which is marketed by Vanda Pharmaceuticals as Hetlioz and developed in partnership with Bristol-Myers Squibb, is a drug that was approved by the US FDA in January 2014 for the treatment of non-24-hour sleep–wake disorder (also called Non-24, N24 and N24HSWD). Tasimelteon is a melatonin MT1 and MT2 receptor agonist; because it exhibits a greater affinity to the MT2 receptor than MT1, is also known as Dual Melatonin Receptor Agonist.234 Two randomized controlled trials (phases II and III) demonstrated that tasimelteon improved sleep latency and maintenance of sleep with a shift in circadian rhythms, and therefore has the potential to treat patients with transient insomnia associated with circadian rhythm sleep disorders. Preclinical studies showed that the drug has similar phase-shifting properties to melatonin, but with less vasoconstrictive effects.
VerwendenTasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.
Anbieter100 Anbieter
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
湖北威德利化学试剂有限公司186-02735115 18062128043 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
上海腾准生物科技有限公司19821570922 · [email protected]
湖北海克斯生化有限公司17362916295; 17362916295 · [email protected]
湖北研科时代科技有限公司15780669880 · [email protected]
湖北科乐精细化工有限公司027-59101668 19945030958 · [email protected]
Zugehörige Reaktionen
7
Notizen zur Verbindung
Wird geladen…